| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Herbacetin-3-sophoroside-8-glucoside contributes to selective antiproliferative effects against oral squamous cell carcinoma cell lines by inducing apoptosis. It maintains low toxicity toward normal cells. It may also target reactive oxygen species (ROS) and inflammatory pathways. Its glycosylation enhances water solubility and bioavailability.
|
|---|---|
| ln Vitro |
In vitro, Herbacetin-3-sophoroside-8-glucoside shows selective antiproliferative activity against oral squamous cell carcinoma cells by inducing apoptosis. It exhibits antioxidant properties by neutralizing reactive oxygen species. It shows low toxicity toward normal cells. It has anti-inflammatory activity through modulation of inflammatory pathways.
|
| ln Vivo |
In vivo studies for Herbacetin-3-sophoroside-8-glucoside are limited. Its antioxidant and anti-inflammatory properties suggest potential for chemoprevention and cancer therapy. The compound's glycosylation enhances its solubility and bioavailability, which may improve its in vivo efficacy. Further animal studies are needed.
|
| Enzyme Assay |
Cell-free assays for Herbacetin-3-sophoroside-8-glucoside: antioxidant activity is evaluated using DPPH, ABTS, and FRAP radical scavenging assays. The compound's ability to neutralize reactive oxygen species is measured by fluorescence-based assays using probes like DCFH-DA. Anti-inflammatory activity is assessed by measuring inhibition of COX-2 or LOX enzyme activities.
|
| Cell Assay |
Cellular assays for Herbacetin-3-sophoroside-8-glucoside: oral squamous cell carcinoma cell lines (e.g., CAL-27, SCC-9) and normal oral keratinocytes are cultured in appropriate media and treated with the compound at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is assessed by MTT assay. Apoptosis is evaluated by Annexin V/PI staining, caspase activity, and PARP cleavage by Western blot. ROS levels are measured using DCFH-DA.
|
| Animal Protocol |
In vivo animal studies for Herbacetin-3-sophoroside-8-glucoside: xenograft mouse models of oral squamous cell carcinoma would be used. Mice are implanted with cancer cells and treated with the compound orally or intraperitoneally at doses of 10-50 mg/kg. Tumor growth, apoptosis markers, and toxicity are assessed. The compound's antioxidant effects in vivo are evaluated by measuring oxidative stress markers in tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Herbacetin-3-sophoroside-8-glucoside: as a glycosylated flavonoid with high molecular weight (788.66), it may have limited oral bioavailability. It may be metabolized by intestinal glycosidases to release the aglycone (herbacetin). The glycosylation may enhance solubility and improve absorption. Further PK studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicity of Herbacetin-3-sophoroside-8-glucoside: it maintains low toxicity toward normal cells. No significant toxicity has been reported. However, comprehensive toxicological studies are lacking. As a natural flavonoid glycoside, it is generally considered safe at moderate doses. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
Herbacetin-3-sophoroside-8-glucoside is a research compound with potential applications in cancer research, particularly for oral squamous cell carcinoma. It is available as a reference standard for pharmacological studies. Its mechanism involves selective induction of apoptosis in cancer cells. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C33H40O22
|
|---|---|
| Molecular Weight |
788.657
|
| Exact Mass |
788.201
|
| CAS # |
77298-68-1
|
| PubChem CID |
11968590
|
| Appearance |
Light yellow to yellow solid powder
|
| Source |
Originated from plants: other families
|
| LogP |
-3
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
55
|
| Complexity |
1330
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
OCC1OC(OC2C(O)C(O)C(CO)OC2Oc2c(oc3c(OC4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3c2=O)-c2ccc(O)cc2)C(O)C(O)C1O
|
| InChi Key |
IQGKZHYKAGWLNS-CVFWACMRSA-N
|
| InChi Code |
InChI=1S/C33H40O22/c34-6-13-17(40)21(44)24(47)31(49-13)53-27-12(39)5-11(38)16-20(43)29(26(52-28(16)27)9-1-3-10(37)4-2-9)54-33-30(23(46)19(42)15(8-36)51-33)55-32-25(48)22(45)18(41)14(7-35)50-32/h1-5,13-15,17-19,21-25,30-42,44-48H,6-8H2/t13-,14-,15-,17-,18-,19-,21+,22+,23+,24-,25-,30-,31+,32+,33+/m1/s1
|
| Chemical Name |
3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~63.4 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (1.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2680 mL | 6.3399 mL | 12.6797 mL | |
| 5 mM | 0.2536 mL | 1.2680 mL | 2.5359 mL | |
| 10 mM | 0.1268 mL | 0.6340 mL | 1.2680 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
